Osilodrostat

ISTURISA is indicated for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: ISTURISA is indicated for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.

Side effects, and when to stop

Clinically significant adverse reactions that appear in other sections of the labeling include:

Hypocortisolism
QT Prolongation
Elevations in Adrenal Hormone Precursors and Androgens

Who should not take it

None.

Storing it

Storage and Handling

Store at room temperature between 20°C to 25°C (68°F to 77°F); excursions permitted 15°C to 30°C (59°F to 86°F); protect from moisture.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Osilodrostat; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/osilodrostat
APA 7th: sofidex. (2026, August 3). Osilodrostat. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/osilodrostat
AMA 11th: Osilodrostat. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/osilodrostat

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.